Trial site
Neuro-Pain Medical Center
- 12running trials
- 10closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Conditions
- Alzheimer disease10 trials
- Parkinson disease4 trials
- Diabetic neuropathy3 trials
- Epilepsy2 trials
- Obesity2 trials
- Frontotemporal dementia1 trial
- Migraine1 trial
- Obstructive sleep apnoea1 trial
- Osteoarthritis1 trial
- Type 2 diabetes1 trial
- Phase
- Phase 313 trials
- Phase 25 trials
- Phase 11 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Completed7 trials
- Recruiting3 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Withdrawn1 trial
- Lead sponsor
- Eli Lilly and Company7 trials
- ACADIA Pharmaceuticals Inc.2 trials
- Cassava Sciences, Inc.2 trials
- SK Life Science, Inc.2 trials
- Vertex Pharmaceuticals Incorporated2 trials
- and 7 more
Running trials
Recruiting
Active, not recruiting
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Active, not recruiting
Active, not recruiting
Recruiting
Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Recruiting
Active, not recruiting
Active, not recruiting
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Alzheimer disease2 recruiting
- Diabetic neuropathy1 recruiting
- Parkinson disease1 recruiting
Closed trials
Completed
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
Withdrawn
A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia
Completed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Completed
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Terminated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Completed
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Terminated
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Completed
Completed
Completed
Site data: ClinicalTrials.govUpdated 18 Nov 2026